Abstract
Colorectal cancer is the second most common cause of cancer-related mortality in the west. The high incidence and mortality make effective prevention an important public-health and economic issue. The regular intake of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with decreased incidence of certain types of cancer particularly those with an inflammatory component, and then are among the few agents known to be chemopreventive. Nitric oxide-releasing non-steroidal anti-inflammatory drugs (NO-NSAIDs) are new chemical entities obtained by adding a nitric oxide-releasing moiety to classical molecules. This new class of molecules has been demonstrated to be much more safe than NSAIDs due to their ability to reduce gastric toxicity. They could therefore represent an alternative to classical NSAIDs treatment. In this review, we sumarise the recent findings in the mechanisms and pathways involved in the antitumoral effects of both NSAIDs and NO-NSAIDs as well as the clinical trials performed with these compounds.
Keywords: nitric oxide-releasing non steroidal anti-inflammatory drugs, anti-tumoral molecules, colorectal cancer, cancer-related mortality, nsaids, no-nsaids, nitric oxide-releasing moiety
Current Cancer Drug Targets
Title: Nitric Oxide-Releasing Non Steroidal Anti-Inflammatory Drugs: A New Generation of Anti-Tumoral Molecules
Volume: 3 Issue: 6
Author(s): Christian Lavagna, Piero Del Soldato, Jean-Luc Burgaud and Patrick Rampal
Affiliation:
Keywords: nitric oxide-releasing non steroidal anti-inflammatory drugs, anti-tumoral molecules, colorectal cancer, cancer-related mortality, nsaids, no-nsaids, nitric oxide-releasing moiety
Abstract: Colorectal cancer is the second most common cause of cancer-related mortality in the west. The high incidence and mortality make effective prevention an important public-health and economic issue. The regular intake of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with decreased incidence of certain types of cancer particularly those with an inflammatory component, and then are among the few agents known to be chemopreventive. Nitric oxide-releasing non-steroidal anti-inflammatory drugs (NO-NSAIDs) are new chemical entities obtained by adding a nitric oxide-releasing moiety to classical molecules. This new class of molecules has been demonstrated to be much more safe than NSAIDs due to their ability to reduce gastric toxicity. They could therefore represent an alternative to classical NSAIDs treatment. In this review, we sumarise the recent findings in the mechanisms and pathways involved in the antitumoral effects of both NSAIDs and NO-NSAIDs as well as the clinical trials performed with these compounds.
Export Options
About this article
Cite this article as:
Lavagna Christian, Soldato Del Piero, Burgaud Jean-Luc and Rampal Patrick, Nitric Oxide-Releasing Non Steroidal Anti-Inflammatory Drugs: A New Generation of Anti-Tumoral Molecules, Current Cancer Drug Targets 2003; 3 (6) . https://dx.doi.org/10.2174/1568009033481750
DOI https://dx.doi.org/10.2174/1568009033481750 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Developments in Chimeric NSAIDs as Anticancer Agents: Teaching an Old Dog a New Trick
Mini-Reviews in Medicinal Chemistry Sphingolipids in Inflammation: Roles and Implications
Current Molecular Medicine Viral Vectors for Cancer Gene Therapy: Viral Dissemination and Tumor Targeting
Current Gene Therapy Targeting Vesicle Trafficking: An Important Approach to Cancer Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery Dexamethasone Reduces Cell Adhesion and Migration of T47D Breast Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Pathobiology and Therapeutic Implications of Tumor Acidosis
Current Medicinal Chemistry Adenoviral Vectors for Cancer Gene Therapy
Current Genomics Cell-free DNA: Characteristics, Detection and its Applications in Myocardial Infarction
Current Pharmaceutical Design Circulatory Estrogen Level Protects Against Breast Cancer in Obese Women
Recent Patents on Anti-Cancer Drug Discovery Tyrosine Hydroxylase Gene: Another Piece of the Genetic Puzzle of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Matrix Metalloproteinases and Colon Anastomosis Repair: A New Indication for Pharmacological Inhibition?
Mini-Reviews in Medicinal Chemistry Cyclodextrin Complexation of Meclizine Hydrochloride and its Influence on the Solubility for its Repurposing
Drug Delivery Letters Inhibitors of Vascular Endothelial Growth Factor in Cancer
Cardiovascular & Hematological Agents in Medicinal Chemistry Translational Peptide-associated Nanosystems: Promising Role as Cancer Vaccines
Current Topics in Medicinal Chemistry Application of the Shortest Path Algorithm for the Discovery of Breast Cancer-Related Genes
Current Bioinformatics Vascular Disrupting Agents (VDA) in Oncology: Advancing Towards New Therapeutic Paradigms in the Clinic
Current Drug Targets Antitumor Properties of Natural Compounds and Related Molecules
Recent Patents on Anti-Cancer Drug Discovery Variances in the Level of COX-2 and iNOS in Different Grades of Endometrial Cancer
Current Pharmaceutical Biotechnology Artificial Intelligence, Big Data and Machine Learning Approaches in Precision Medicine & Drug Discovery
Current Drug Targets Prospective Role of MicroRNAs in Depression
Current Medicinal Chemistry